M&As this week: Allergan, Roche Holdings, Pharmaron
Irish pharmaceutical company Allergan has entered an option agreement with the shareholders of US-based Lysosomal Therapeutics (LTI), giving the former the right to acquire the latter.
LTI is engaged in small-molecule research and development targeting neurodegeneration diseases.
The acquisition will take place upon completion of a Phase I b trial for LTI-291, LTI’s lead programme that targets Parkinson’s Disease.
Allergan will make an upfront research and development payment for the drug candidate, as part of the agreement and the two companies will form a joint committee that will oversee LTI-291’s development.
Allergan expects to enter the Parkinson’s Disease market through the acquisition.
US-based biotechnology company ForSight VISION4 has been acquired by Roche Holdings for an upfront payment in addition to earn-out payments based on the achievement of certain development and commercial milestones.
Roche will gain access to the target company’s PDS technology, which is used for long-acting delivery of therapeutics to the eye.
Roche has acquired the company from US-based medical device organisation ForSight Labs.
US-based contract research company Pharmaron has completed the acquisition of biotechnology company Xceleron.
Through the acquisition, Pharmaron aims to differentiate and strengthen its offerings in translational science and clinical development services, as well as research and development (R&D) collaborations worldwide.